SLC25A52: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: SLC25A52

NCBI ID: G147407

SLC25A52

SLC25A52: A Potential Drug Target and Biomarker for Neurological Disorders

SLC25A52 (Mitochondrial carrier triple repeat 2) is a protein that is expressed in the brain and is known for its role in the transport of various molecules, including neurotransmitters, across the blood-brain barrier. It is also a key component of the mitochondrial outer membrane, which is responsible for maintaining the structural integrity of the mitochondria and is involved in a wide range of cellular processes.

SLC25A52 has been identified as a potential drug target due to its involvement in the transmission of various neurotransmitters across the blood-brain barrier. Studies have shown that SLC25A52 is expressed in the brain and that it is involved in the uptake and transportation of neurotransmitters, such as dopamine, across the blood-brain barrier. This suggests that SLC25A52 could be a useful target for the treatment of neurological disorders that are characterized by the over-expression of neurotransmitters or the disruption of their normal transport across the blood-brain barrier.

In addition to its role in neurotransmission, SLC25A52 is also involved in the maintenance of the structural integrity of the mitochondria. Mitochondria are responsible for generating the energy that is used by cells and are involved in a wide range of cellular processes, including metabolism and neurotransmission. The structure and function of the mitochondria are essential for the survival of the cell, and changes in their structure or function can have a profound impact on the health and survival of the cell.

SLC25A52 is also of interest as a potential biomarker for certain neurological disorders. The blood-brain barrier is a specialized barrier that separates the brain from the blood and is designed to prevent the entry of foreign particles, including neurotransmitters. However, in some neurological disorders, such as Alzheimer's disease, the blood-brain barrier becomes too permeable and allows the over-expression of neurotransmitters, leading to the disruption of normal brain function. SLC25A52 has been shown to be involved in the uptake and transportation of neurotransmitters across the blood-brain barrier, and therefore, could be a useful biomarker for the diagnosis and treatment of certain neurological disorders.

In conclusion, SLC25A52 is a protein that is expressed in the brain and is involved in the transport of neurotransmitters across the blood-brain barrier. Its involvement in the maintenance of the structure and function of the mitochondria makes it a potential drug target, and its role as a biomarker for certain neurological disorders makes it an attractive target for the development of new treatments. Further research is needed to fully understand the role of SLC25A52 in the brain and its potential as a drug and biomarker.

Protein Name: Solute Carrier Family 25 Member 52

Functions: Mitochondrial membrane carrier protein that mediates the import of NAD(+) into mitochondria (PubMed:32906142). Compared to SLC25A51, SLC25A52-mediated transport is not essential for the import of NAD(+) in mitochondria (PubMed:32906142)

The "SLC25A52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets